- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Arch Biopartners Inc: Arch partner TGH receives approval for phase II trial | 1 | Stockwatch | ||
| Di | Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) | 1 | GlobeNewswire (USA) | ||
| 11.04. | Arch Biopartners Inc: Arch Biopartners 235,000-share private placement | 2 | Stockwatch | ||
| 14.03. | Arch Biopartners Inc: Arch Biopartners closes $374,000 private placement | 1 | Stockwatch | ||
| 14.03. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 05.03. | Arch Biopartners Inc: Arch Biopartners arranges $350,000 private placement | 1 | Stockwatch | ||
| 05.03. | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 26.02. | Arch Biopartners Inc: Arch Biopartners 31,112 shares for debt | 1 | Stockwatch | ||
| 18.02. | Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) | 80 | GlobeNewswire (Europe) | TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming investigator-led... ► Artikel lesen | |
| 04.02. | Arch Biopartners Inc: Arch Biopartners arranges $57,246 shares for debt deal | 1 | Stockwatch | ||
| 03.02. | Arch Biopartners: Shares for Interest Debt Settlement | 1 | GlobeNewswire (USA) | ||
| 08.01. | Arch Biopartners Inc: Arch receives OK to proceed with phase II LSALT trial | 1 | Stockwatch | ||
| 08.01. | Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | 106 | GlobeNewswire (Europe) | TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics... ► Artikel lesen | |
| 21.11.24 | Arch Biopartners Inc: Arch Biopartners 250,323-share private placement | 2 | Stockwatch | ||
| 11.11.24 | Arch Biopartners Inc: Arch Biopartners begins patient dosing for LSALT trial | 1 | Stockwatch | ||
| 11.11.24 | Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 133 | GlobeNewswire (Europe) | TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in... ► Artikel lesen | |
| 02.08.24 | Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins | 130 | GlobeNewswire (Europe) | Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,020 | -1,57 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,480 | -36,02 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,860 | -2,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 50,000 | +0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | ||
| TEMPUS AI | 52,90 | -1,13 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,740 | -0,42 % | Hohes Potenzial: Merck KGaA vor Milliarden-Deal: US-Krebsspezialist SpringWorks im Visier | © Foto: Arne Dedert/dpaDer deutsche Pharmakonzern Merck plant den Kauf eines vielversprechenden US-Wettbewerbers. Die Gelegenheit ist günstig.Der Darmstädter Pharma- und Technologiekonzern Merck KGaA... ► Artikel lesen | |
| EVOTEC | 7,382 | +0,52 % | Aktien KW 16 Erholung. Aber: Death Cross als Crash-Menetekel? Oder gibt's Hoffnung? News. Rheinmetall. Kontron. Evotec. Nvidia. Hamborner REIT. MHP Hotels. Forvia Hella. Hensoldt. Circus. Berentzen. Fortec. Carl Zeiss MediTec. Drägerwerk. Agnicio Mining | Aktien Wochenrückblick - die Märkte scheinen sich langsam an die Zitterphase zu gewöhnen. Aktuelle Kurserholung dauerhaft? Oder was kommt noch: Zollankündigung, Handelskrieg mit China, 90 Tage Moratorium... ► Artikel lesen | |
| BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,060 | -0,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy | - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 29,610 | +0,61 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
| VERVE THERAPEUTICS | 5,760 | -0,35 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
| RECURSION PHARMACEUTICALS | 5,740 | -0,17 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
| VIR BIOTECHNOLOGY | 6,120 | -2,70 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| CG ONCOLOGY | 22,400 | +4,04 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,200 | +0,31 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen |
ARCH BIOPARTNERS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.
